title: [Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis].
abstract: Etanercept (Enbrel) is a soluble tumour necrosis factor (TNF) receptor drug. By this mechanism, it inhibits the effects of TNF-alpha involved in the pathogenesis of psoriasis. Enbrel is approved for the treatment of moderate to severe chronic plaque psoriasis, and also for psoriatic arthritis.
authors: Service de Dermatopathologie, CHU du Sart Tilman, Liège. Claudine.Franchimont@ulg.ac.be
authors: C
authors: C
authors: Piérard-Franchimont
authors: G E
authors: GE
authors: Piérard